Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID‐19 Patients: A Perspective from an Israeli Cross‐Sector Collaboration-Reference-Cited by-同舟云学术

Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID‐19 Patients: A Perspective from an Israeli Cross‐Sector Collaboration

Published:2022-05-05 Issue:6 Volume:112 Page:1156-1158
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Guy‐Alfandary Shiri¹,Zhurat Sasha²,Berlin Maya²,De Haan Tal²,Gueta Itai³,Shihmanter Renata⁴,Golik Ahuva⁵,Berkovitch Matitiahu²,Eyal Sara⁶,Goldstein Lee H.⁷

Affiliation:

1. Health Division Pharmacy and Pharmacology Department Maccabi Healthcare Services Tel‐Aviv Israel

2. Clinical Pharmacology and Toxicology Unit Shamir Medical Center (Assaf Harofeh) Affiliated to Sackler Faculty of Medicine Tel‐Aviv University Tel Aviv Israel

3. The Institute of Clinical Pharmacology and Toxicology Internal Medicine A, Sheba Medical Center, Tel Hashomer, Israel, Affiliated to Sackler Faculty of Medicine, Tel‐Aviv University Tel Aviv Israel

4. Clinical Pharmacology Unit Kaplan Medical Center, Rehovot, Israel, Affiliated to The Hebrew University of Jerusalem Jerusalem Israel

5. Adelson School of Medicine Ariel University Ariel Israel

6. Institute for Drug Research School of Pharmacy The Hebrew University of Jerusalem Jerusalem Israel

7. Clinical Pharmacology Unit Haemek Medical Center, Afula, Israel, Affiliated to The Bruce Rapapport School of Medicine Technion Israel

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2610

Reference10 articles.

1. FDA.Fact sheet for healthcare providers: emergency use authorization for paxlovid. Revised December 22 2021. Accessed February 18 2021.

2. Using nirmatrelvir/ritonavir in patients with epilepsy: An update from the Israeli chapter of the International League Against Epilepsy

3. Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies

4. Dose–Response of Ritonavir on Hepatic CYP3A Activity and Elvitegravir Oral Exposure

5. FDA.Drug development and drug interactions: table of substrates inhibitors and inducers (2020). March 10 2020. Accessed January 21 2022.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacist's role in the management of drug–drug interactions caused by nirmatrelvir/ritonavir in COVID-19 oncohematology patients;Journal of Oncology Pharmacy Practice;2024-03-07

2. Nirmatrelvir/ritonavir drug-drug interactions in primary care outpatients;Anales del Sistema Sanitario de Navarra;2023-12-26

3. The extent of cytochrome P450 3A induction by antiseizure medications: A systematic review and network meta‐analysis;Epilepsia;2023-12-11

4. VV116 as a potential treatment for COVID-19;Expert Opinion on Pharmacotherapy;2023-03-20

5. Understanding the Risk of Drug Interactions Between Ritonavir-Containing COVID-19 Therapies and Small-Molecule Kinase Inhibitors in Patients With Cancer;JCO Precision Oncology;2023-02